Comparing two types of neobladder surgeries for bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares the safety and efficacy of two surgical techniques for creating a neobladder: the detaenial sigmoid neobladder and the ileal neobladder. Patients with muscle invasive bladder cancer or recurrent bladder cancer will undergo one of the two procedures after radical cystectomy. The study aims to evaluate the outcomes related to patient survival and quality of life following these surgical interventions. Participants will be monitored for complications and overall effectiveness of the surgeries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Bladder carcinoma in situ, include CIS and T1G3 tumor, muscle invasive bladder cancer（T2/T3N0-1M0）
2. Recurrent bladder cancer
3. Other conditions that have been approved by a urologist for indications for new bladder surgery
4. Had been received intravesical chemotherapy, intra-arterial infusion chemotherapy or systemic chemotherapy in the past.
5. Voluntarily signed the informed consent -

Exclusion Criteria:

1. Preoperative serum creatinine more than 2.26mg/dl（Or 200μmol/L）
2. Cancer invaded urethral (confirmed by the pathology)
3. Non - bladder cancer patients underwent neobladder
4. A history of other malignant tumors within five years
5. Ileum / sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
6. Other conditions that have been approved by a urologist for not suitable for new bladder surgery

   \-

Where it's running

• Zhujiang Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Abai Xu, doctor — Zhujiang Hospital
• Study coordinator: Abai Xu, doctor
• Email: lc96xab@163.com
• Phone: +86 18665626790

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observing quality of life in patients after bladder cancer surgery

  This study looks at how bladder cancer surgery affects the quality of life for patients over about 10 years by checking in with them each year.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT06170177

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.